Dr. Anna Vilgelm is a cancer biologist with experience in basic and translational studies. The main focus of Dr. Vilgelm's research is on pre-clinical development of effective strategies for metastatic cancer treatment. Currently, Vilgelm laboratory investigates ways to stimulate anti-tumor immunity by inducing “hot”, immune-cell enriched, tumor micro-environment. Specifically, modulation of molecular mechanisms controlling tumor secretome in explored. In addition Dr. Vilgelm's research team is developing personalized medicine approaches to induce synthetic lethality in tumor cells using rational drug combinations. They utilize a variety of pre-clinical research models including 3D organoid cultures of patient's tumor cells and humanized patient-derived models. Our ultimate goal is to develop new therapeutic approaches to stimulate anti-tumor immunity that prevents tumor relapses resulting in long lasting disease control.
2018-2025 NCI MERIT (R37) award
2017-2020 Breast Cancer Research Foundation award
Academic and Medical Appointments
2019-Present Assistant Professor, Department of Pathology, The Ohio State University Wexner Medical Center
2017-2019 Research Assistant Professor, Department of Pharmacology, Vanderbilt University
2015-2017 Research Assistant Professor, Department of Cancer Biology, Vanderbilt University
Education and Training
2011-2015 Postdoctoral Fellow, Cancer Biology, Vanderbilt University
2006-2011 Ph.D., Molecular Biology, Vanderbilt University and Engelhardt Institute of Molecular Biology
2005 M.D., Medical Biochemistry, Russian National Research Medical University
Search in PubMed
- Vilgelm AE*, Saleh N, Riemenschneider K, Slesur L, Chen S, Johnson C, Yang J, Shattuck-Brandt R, Yan C, Johnson D, Al-Rohil R, Halilovic E, Kauffmann R, Kelley M, Ayers G, Richmond A. " MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21". Science Translational Medicine, August 2019. * - corresponding author
- Vilgelm AE, Richmond A. “Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis and Response to Immunotherapy”. Frontiers in Immunology, February 2019.
- Yang J, Kumar A, Vilgelm AE, Chen SC, Ayers GD, Novitskiy SV, Joyce S, Richmond A. “Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms.” Cancer Immunol Res., August 14, 2018.
- Vilgelm AE*, Cobb P, Malikayil K, Flaherty D, Johnson CA, Raman D, Saleh N, Higgins B, Vara BA, Johnston JN, Johnsonh DB, Kelley MC, Chen SC, AyersGD, Richmond A. “MDM2 Antagonists Counteract Drug-Induced DNA Damage.” EBioMedicine, October 24, 2017. * - corresponding author
- Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M, Richmond A. “PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.” Clin Cancer Res., Dec 21, 2016.
- Vilgelm, A. E.*, Johnson, D. B., Richmond, A. “Combinatorial approach to cancer immunotherapy: strength in numbers.” J Leukoc Biol., Jun 2, 2016. * - corresponding author
- Vilgelm, A. E. and Richmond, A. “Using avatars to win the fight over BRAF inhibitor resistance.” Pigment Cell Melanoma Res., May 17, 2016.
- Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM. “Melanoma-specific MHC-II expression represents a tumor-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy”. Nat Commun. Jan 29, 2016.
- Vilgelm, A. E.*, Johnson, C. A., Prasad, N., Yang, J., Chen, S. C., Ayers, G. D., Pawlikowski, J. S., Raman, D., Sosman, J. A., Kelley, M., Ecsedy, J. A., Shyr, Y., Levy, S. E., Richmond, A. “Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.” J Natl Cancer Inst., Dec 30, 2016. * - corresponding author
- Vilgelm A, Richmond A. “Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses.” Oncoimmunology, Mar 19, 2015.
- Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A. “Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models”. Clin Cancer Res., Jul 7, 2015.
- Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart SF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN and Richmond A. “Mdm2 and Aurora A inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells”. Cancer Res., Jan 1 2015.
- Hockemeyer, K, Janetopoulous C, Terekhor A, Vilgelm AE, Hofmeister W, Wikswo J, Richmond A. “Engineered three-dimensional microfluidic device for interrogating cell-cell interactions in the tumor microenvironment.” Biomicrofluidics, Jul 15, 2014.
- Davis TA, Vilgelm AE, Richmond A, Johnston JN. “A Practical Preparation of (–)-Nutlin-3 at Gram-Scale” J Org Chem., Nov 1, 2013.
- Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC, Richmond A. “Targeting Aurora Kinases Limits Tumor Growth through DNA Damage Mediated Senescence and Blockade of NF-κB Impairs Senescence.” EMBO Mol Med., Jan 5, 2013.
- Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A. “RAF265 inhibits the growth of advanced human melanoma tumors”. Clin Cancer Res., Apr 15, 2012.
- Vilgelm AE, Hong SM, Washington MK, Wei J, Chen H, El-Rifai W, Zaika A. “Characterization of ΔNp73 expression and regulation in gastric and esophageal tumors.” Oncogene., Oct 28, 2010.
- Vilgelm AE, Zaika AI, Prassolov VS. “The coordinated interaction of multifunctional members of the p53 family determines many key processes in multicellular organisms.” Mol Biol (Mosk). Jan-Feb 2011. Review.
- Vilgelm AE, Washington MK, Wei J, Chen H, Prassolov VS, Zaika AI. “Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors.” Mol Cancer Ther., Mar 9, 2010.
- Vilgelm A, El-Rifai W, Zaika A. “Therapeutic prospects for p73 and p63: rising from the shadow of p53.” Drug Resist Updat., Aug-Oct 2008. Review.